Clinical trials and in vitro studies in other types of B cell lymphomas are thus warranted to further strengthen the mechanistic and clinical connections among residual tumor cells, suppressed GC reaction, and peripheral BCR IR population. The gene discussed is BCR; the disease is neoplasm.